Insider Selling: Edwards Lifesciences Corp. CEO Sells 29,500 Shares of Stock (EW)
Edwards Lifesciences Corp. (NYSE:EW) CEO Michael Mussallem sold 29,500 shares of Edwards Lifesciences Corp. stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $71.82, for a total transaction of $2,118,690.00. Following the completion of the transaction, the chief executive officer now directly owns 263,850 shares in the company. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
EW has been the subject of a number of recent research reports. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of Edwards Lifesciences Corp. (NYSE:EW) in a research note to investors on Tuesday, September 10th. They now have a $90.00 price target on the stock. Separately, analysts at RBC Capital raised their price target on shares of Edwards Lifesciences Corp. (NYSE:EW) from $72.00 to $75.00 in a research note to investors on Tuesday, September 10th. They now have a “sector perform” rating on the stock. Finally, analysts at Zacks upgraded shares of Edwards Lifesciences Corp. (NYSE:EW) from an “underperform” rating to a “neutral” rating in a research note to investors on Thursday, August 29th. They now have a $74.00 price target on the stock.
One analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $80.69.
Edwards Lifesciences Corp. (NYSE:EW) traded up 0.01% during mid-day trading on Monday, hitting $71.62. 715,902 shares of the company’s stock traded hands. Edwards Lifesciences Corp. has a 52 week low of $62.34 and a 52 week high of $110.79. The stock’s 50-day moving average is $71.68 and its 200-day moving average is $72.68. The company has a market cap of $8.041 billion and a P/E ratio of 20.93.
Edwards Lifesciences Corp. (NYSE:EW) last announced its earnings results on Thursday, July 25th. The company reported $0.82 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.76 by $0.06. The company had revenue of $517.20 million for the quarter, compared to the consensus estimate of $514.59 million. During the same quarter in the prior year, the company posted $0.57 earnings per share. The company’s quarterly revenue was up 7.3% on a year-over-year basis. Analysts expect that Edwards Lifesciences Corp. will post $3.07 EPS for the current fiscal year.
Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.